104 related articles for article (PubMed ID: 35607995)
21. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals.
Healy K; Pin E; Chen P; Söderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Österborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Loré K; Hellström C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren HG; Hober S; Nilsson P; Aleman S; Sällberg Chen M
Med; 2022 Feb; 3(2):137-153.e3. PubMed ID: 35075450
[TBL] [Abstract][Full Text] [Related]
22. Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers.
Benning L; Morath C; Bartenschlager M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schaier M; Klein K; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Speer C
Clin Microbiol Infect; 2022 Jul; 28(7):1024.e7-1024.e12. PubMed ID: 35124261
[TBL] [Abstract][Full Text] [Related]
23. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM; Koff JL; Blum KA; Ayers AA; O'Leary CB; Churnetski MC; Sulaiman S; Kives M; Sheng P; Davis CW; Nooka AK; Antia R; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
J Clin Oncol; 2022 Sep; 40(26):3020-3031. PubMed ID: 35436146
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.
Franzese M; Coppola L; Silva R; Santini SA; Cinquanta L; Ottomano C; Salvatore M; Incoronato M
Front Immunol; 2022; 13():947187. PubMed ID: 36248864
[TBL] [Abstract][Full Text] [Related]
25. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
[TBL] [Abstract][Full Text] [Related]
26. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
Front Immunol; 2022; 13():908108. PubMed ID: 35911701
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant.
Peled Y; Afek A; Kreiss Y; Rahav G; Nemet I; Kliker L; Indenbaum V; Ram E; Lavee J; Segev A; Matezki S; Sternik L; Raanani E; Lustig Y; Patel JK; Mandelboim M
J Heart Lung Transplant; 2022 Oct; 41(10):1417-1425. PubMed ID: 35710484
[TBL] [Abstract][Full Text] [Related]
28. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
29. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
[TBL] [Abstract][Full Text] [Related]
30. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2.
Speer C; Göth D; Benning L; Buylaert M; Schaier M; Grenz J; Nusshag C; Kälble F; Kreysing M; Reichel P; Töllner M; Hidmark A; Ponath G; Schnitzler P; Zeier M; Süsal C; Morath C; Klein K
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1073-1082. PubMed ID: 34031181
[TBL] [Abstract][Full Text] [Related]
31. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
32. Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation.
Peled Y; Afek A; Nemet I; Rahav G; Raanani E; Patel JK; Mandelboim M
J Heart Lung Transplant; 2022 Sep; 41(9):1210-1213. PubMed ID: 35794051
[TBL] [Abstract][Full Text] [Related]
33. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.
Cohen H; Rotem S; Elia U; Bilinsky G; Levy I; Chitlaru T; Bar-Haim E
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215940
[TBL] [Abstract][Full Text] [Related]
34. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
Lu L; Mok BWY; Chen LL; Chan JMC; Tsang OTY; Lam BHS; Chuang VWM; Chu AWH; Chan WM; Ip JD; Chan BPC; Zhang R; Yip CCY; Cheng VCC; Chan KH; Jin DY; Hung IFN; Yuen KY; Chen H; To KKW
Clin Infect Dis; 2022 Aug; 75(1):e822-e826. PubMed ID: 34915551
[TBL] [Abstract][Full Text] [Related]
35. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
36. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
37. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.
Massa F; Cremoni M; Gérard A; Grabsi H; Rogier L; Blois M; Couzin C; Hassen NB; Rouleau M; Barbosa S; Martinuzzi E; Fayada J; Bernard G; Favre G; Hofman P; Esnault VLM; Czerkinsky C; Seitz-Polski B; Glaichenhaus N; Sicard A
EBioMedicine; 2021 Nov; 73():103679. PubMed ID: 34763205
[TBL] [Abstract][Full Text] [Related]
38. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients.
Becker M; Cossmann A; Lürken K; Junker D; Gruber J; Juengling J; Ramos GM; Beigel A; Wrenger E; Lonnemann G; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Strengert M; Dulovic A; Behrens GMN
Front Immunol; 2022; 13():1004045. PubMed ID: 36275672
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
